The European Commission and the World Health Organization, among others, often seek the views and opinions of citizens and stakeholders through so-called public consultations when they develop policy and legislation.
The objective of public consultations is to provide external stakeholders and citizens an opportunity to provide input early in the decision-making process to express views on the scope, priorities and added value of new initiatives, or evaluations of existing policies and laws. The input of oncology experts in this process is crucial in order to represent the field of cancer, and help influence and shape legislation at EU and global levels. The results of public consultations guide the EU and WHO’s work throughout the policy cycle.
ESMO has submitted several responses to various consultations in order to express the needs and views of the oncology community on the areas European and global health authorities need to work on, which you can find below.
ESMO Responses
Artificial intelligence:
- ESMO response to the consultation on the proposal for the Artificial Intelligence Act (August 2021)
- More information: European Commission website
Asbestos:
- ESMO response to the consultation on the legislative proposal for revising the Asbestos at Work Directive (November 2022)
- More information: European Commission website
European Health Data Space:
- ESMO response to the consultation on the legislative proposal for the European Health Data Space (July 2022)
- ESMO response to the consultation on the European Health Data Space (July 2021)
- More information: European Commission website
EU rules on medicines for children and rare diseases:
- ESMO response to the consultation on the revision of EU rules on medicines for children and rare diseases (July 2021)
- More information: European Commission website
Cross-border healthcare:
- ESMO response to the consultation on the evaluation of patient rights in cross-border healthcare (July 2021)
- ESMO response to the roadmap on the evaluation of patient rights in cross-border healthcare (February 2021)
- More information: European Commission website
EU Pharmaceuticals Legislation:
- ESMO response to the roadmap & inception impact assessment on the revision of the EU general pharmaceuticals legislation (April 2021)
- More information: European Commission website
European Medicines Agencies Network Strategy:
- ESMO response to the consultation on the European Medicines Agencies Network Strategy to 2025 (September 2020)
- More information: European Medicines Agency’s website
Pharmaceutical Strategy for Europe:
- ESMO response to the roadmap for the Pharmaceutical Strategy (July 2020)
- ESMO response to the Pharmaceutical Strategy for Europe (July 2020)
- More information: European Commission website
Europe’s Beating Cancer Plan:
- ESMO response to the roadmap for Europe’s Beating Cancer Plan (March 2020)
- More information: European Commission website